This brand name is authorized in Cyprus
The drug LACROMID contains one active pharmaceutical ingredient (API):
|
1
Bezafibrate
UNII Y9449Q51XH - BEZAFIBRATE
|
|
Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| LACROMID Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C10AB02 | Bezafibrate | C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
